The positive metabolic effects of OXM, characterized by increased insulin secretion and reduced glycaemic excursion, appeared comparable to liraglutide in individuals with obesity and type 2 diabetes (Pocai et al., 2009). The gene discussed is GCG; the disease is obesity disorder.